Have a personal or library account? Click to login
The Use of Methotrexate in Dermatology / Upotreba metotreksata u dermatologiji Cover

The Use of Methotrexate in Dermatology / Upotreba metotreksata u dermatologiji

Serbian Journal of Dermatology and Venereology
Volume 3 (2011): Issue 4 (December 2011)
By: Jagoda Balaban  
Open Access
|Feb 2013

References

  1. 1. Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007;20(4): 216-28.10.1111/j.1529-8019.2007.00135.x17970887
    Search in Google Scholar
  2. 2. Milojević M. Citotoksična sredstva. U: Karadaglić Đ.Dermatologija. Beograd: Vojnoizdavački zavod; 2000. str. 2251-6.
    Search in Google Scholar
  3. 3. Barker J, Horn EJ, Lebwohl M, Warren RB,Nast A, Rosenberg W, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011;25(7):758-64.10.1111/j.1468-3083.2010.03932.x21198946
    Search in Google Scholar
  4. 4. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological diseasemodifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009;68(7):1105-12.10.1136/ard.2008.099861268952619054823
    Search in Google Scholar
  5. 5. Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatology 2007;46(10):1520-4.10.1093/rheumatology/kem14717586865
    Search in Google Scholar
  6. 6. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009;67(1):44-9.10.1111/j.1365-2125.2008.03303.x266808319076159
    Search in Google Scholar
  7. 7. Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology 2009;48(5):569-72.10.1093/rheumatology/kep02319273538
    Search in Google Scholar
  8. 8. Berends MA, Snoek J, de Jong EM, van de Kerkhof PC, van Oijen MG, van Krieken JH, et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther 2006;24(5):805-11.10.1111/j.1365-2036.2006.03047.x16918884
    Search in Google Scholar
  9. 9. Carneiro SC, Cassia FF, Lamy F, Chagas VL, Ramos-e-Silva M. Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages. J Eur Acad Dermatol Venereol 2008;22(1):25-9.
    Search in Google Scholar
  10. 10. Thomas JA, Aithal GP. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Am J Clin Dermatol 2005;6(6):357-63.
    Search in Google Scholar
  11. 11. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009;160(3):622-8.10.1111/j.1365-2133.2008.08876.x18945303
    Search in Google Scholar
  12. 12. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol 2006;55(2):366-7.10.1016/j.jaad.2006.01.07216844540
    Search in Google Scholar
  13. 13. Kozub P, Simaljakova M. Systemic therapy of psoriasis: methotrexate. Bratisl Lek Listy 2011;112(7):390-4.
    Search in Google Scholar
  14. 14. Morgan SL, Baggott JE. Folate supplementation during methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2010;28(61):102-9.
    Search in Google Scholar
  15. 15. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol 2000;14(5):382-8.10.1046/j.1468-3083.2000.00058.x11305380
    Search in Google Scholar
  16. 16. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60(5):824-37.10.1016/j.jaad.2008.11.90619389524
    Search in Google Scholar
  17. 17. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.10.1016/j.jaad.2009.03.02719493586
    Search in Google Scholar
  18. 18. Chladek J, Simkova M, Vaneckova J, Hroch M, ChladkovaJ, Martinkova J, et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008;64(4):347-55.10.1007/s00228-007-0442-x18163165
    Search in Google Scholar
  19. 19. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 2006;54(6):1013-8.10.1016/j.jaad.2006.01.00416713455
    Search in Google Scholar
  20. 20. Jager ME, Jong EM, Kerkhof PC, Seyger MM. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010;62(6):1013-30.10.1016/j.jaad.2009.06.04819900732
    Search in Google Scholar
  21. 21. Collin B, Vani A, Ogboli M, Moss C. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol 2009;34(3):295-8.10.1111/j.1365-2230.2008.02907.x19175782
    Search in Google Scholar
  22. 22. Syed TA, Hadi SM, Qureshi ZA, Nordstrom CG, Ali SM. Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study. J Cutan Med Surg 2001;5(4):299-302.10.1177/120347540100500403
    Search in Google Scholar
  23. 23. Patton T, Korman N. Role of methotrexate in the treatment of bullous pemphigoid in the elderly. Drugs Aging 2008;25(8):623-9.10.2165/00002512-200825080-0000118665656
    Search in Google Scholar
  24. 24. Mutasim DF. Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management. Drugs Aging 2010;27(1):1-19.10.2165/11318600-000000000-0000020030429
    Search in Google Scholar
  25. 25. Marie I. Therapy of polymyositis and dermatomyositis. Presse Med 2011;40(4):257-70.10.1016/j.lpm.2010.12.01221334847
    Search in Google Scholar
  26. 26. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009;10(6):365-81.10.2165/11310780-000000000-0000019824738
    Search in Google Scholar
  27. 27. Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol 2010;11(3):157-70.10.2165/11530070-000000000-0000020184391
    Search in Google Scholar
  28. 28. Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs 2008;68(10):1361-83.10.2165/00003495-200868100-0000318578557
    Search in Google Scholar
  29. 29. Krunić A. Keratoakantom. U: Karadaglić Đ. Dermatologija. Beograd: Vojnoizdavački zavod; 2000. str. 834-41.
    Search in Google Scholar
  30. 30. Graham RM. Reiter’s disease. In: Rook A, Wilkinson DS, Ebling FJG, Champion RH, Burton JL, editors. Textbook ofdermatology. 5th ed. Oxford: Blackwell Scientific Publications; 1992. p. 2455-67.
    Search in Google Scholar
  31. 31. Mestel DS, Beyer M, Steinhoff M, Sterry W,Assaf C.The treatment of mycosis fungoides. Ital Dermatol Venereol 2008;143(6):395-408.
    Search in Google Scholar
  32. 32. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 2007;33(2):146-60.10.1016/j.ctrv.2006.08.00617275192
    Search in Google Scholar
  33. 33. Yazici H, Fresko I, Yurdakul S. Behcet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 2007;3(3):148-55.10.1038/ncprheum043617334337
    Search in Google Scholar
  34. 34. Zoller L, Ramon M, Bergman R. Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema. Isr Med Assoc J 2008;10(6):413-4.
    Search in Google Scholar
  35. 35. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-tosevere adult atopic eczema. Br J Dermatol 2007;156(2):346-51.10.1111/j.1365-2133.2006.07686.x17223876
    Search in Google Scholar
  36. 36. Beltramelli M, Vercellesi P, Frasin A, Gelmetti C, Corona F. Localized severe scleroderma: a retrospective study of 26 pediatric patients. Pediatr Dermatol 2010;27(5):476-80.10.1111/j.1525-1470.2010.01258.x20796242
    Search in Google Scholar
  37. 37. Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM. Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol 2009;160(5):1075-82.10.1111/j.1365-2133.2008.09017.x19210503
    Search in Google Scholar
  38. 38. Jang N, Fischer G. Treatment of erosive vulvovaginal lichen planus with methotrexate. Australas J Dermatol 2008;49(4):216-9.10.1111/j.1440-0960.2008.00472.x18855784
    Search in Google Scholar
  39. 39. Sharma VK, Bhat R, Sethuraman G, Manchanda Y. Treatment of parthenium dermatitis with methotrexate. Contact Dermatitis 2007;57(2):118-9.10.1111/j.1600-0536.2006.00950.x17627653
    Search in Google Scholar
  40. 40. Kacar N, Tasli L, Argenziano G, Demirkan N. Reticulohistiocytosis: different dermatoscopic faces and a good response to methotrexate treatment. Clin Exp Dermatol 2010;35(4):120-2.10.1111/j.1365-2230.2009.03738.x19886958
    Search in Google Scholar
  41. 41. Lazaridou E, Fotiadou C, Tsorova C, Trachana M, Trigoni A, Patsatsi A, et al. Resistant pityriasis lichenoides et varioliformis acuta in a 3-year-old boy: successful treatment with methotrexate. Int J Dermatol 2010;49(2):215-7.10.1111/j.1365-4632.2009.04325.x20465649
    Search in Google Scholar
DOI: https://doi.org/10.2478/v10249-011-0045-5 | Journal eISSN: 2406-0631
Journal RSS Feed
Language: English
Page range: 137 - 144
Published on: Feb 12, 2013
Published by: Serbian Association of Dermatovenereologists (SAD)
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Methotrexate,
administration and dosage,
adverse effects,
pharmacokinetics,
therapeutic use,
toxicity,
Skin Diseases,drug therapy,
Dermatology,
Dermatologic Agents
Related subjects:
Medicine,
Clinical medicine,
Dermatological and veneral diseases

© 2013 Jagoda Balaban, published by Serbian Association of Dermatovenereologists (SAD)
This work is licensed under the Creative Commons License.

Volume 3 (2011): Issue 4 (December 2011)Next article